The symptoms reported were similar, except for nausea and vomiting which showed a trend towards lesser severity in A, and overall condition which was rated higher in A, particularly following the second and subsequent cycles (Table 4).
← all excerpts
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
1
—
—